Abstract
Eosinophils have been recognized to be associated with various immune responses and disease processes including bronchial asthma. Eosinophils release a number of cytotoxic and neurotoxic mediators. However, the factors regulating such release and the underlying mechanisms are unclear. In this study, we investigated the effect of a selective and potent thromboxane synthase inhibitor, DP-1904, on the release of eosinophil cationic protein (ECP) in platelet activating factor (PAF) and IgG-stimulated human blood eosinophils. PAF (1 μM) and IgG both released ECP which constituted about 25-30% of the total ECP content. The control protein, ovalbumin, did not release any ECP over the basal values. DP-1904 in two different concentrations, 10 μM and 100 μM, significantly attenuated the release of ECP in response to PAF or IgG. The mean percent inhibition by 10 μM DP-1904 was 49 ± 10 and 31 ± 2 against PAF and IgG-induced ECP release, respectively. However, at 100 μM DP-1904 the percent inhibition was 76 ± 14 and 67 ± 2, respectively. These data suggest that TXA2 is an important mediator in the regulation of eosinophil degranulation, and DP-1904 thus might prove beneficial in the treatment of bronchial asthma.
| Original language | English |
|---|---|
| Pages (from-to) | 1-8 |
| Number of pages | 8 |
| Journal | Inflammation |
| Volume | 21 |
| Issue number | 1 |
| DOIs | |
| State | Published - 1997 |
Fingerprint
All Science Journal Classification (ASJC) codes
- Cell Biology
- Immunology
- Medicine(all)
Cite this
A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation. / Agrawal, Devendra K.; Takami, Mitsutaka; Ono, Shin Etsu.
In: Inflammation, Vol. 21, No. 1, 1997, p. 1-8.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - A novel thromboxane synthetase inhibitor, DP-1904, inhibits human blood eosinophil degranulation
AU - Agrawal, Devendra K.
AU - Takami, Mitsutaka
AU - Ono, Shin Etsu
PY - 1997
Y1 - 1997
N2 - Eosinophils have been recognized to be associated with various immune responses and disease processes including bronchial asthma. Eosinophils release a number of cytotoxic and neurotoxic mediators. However, the factors regulating such release and the underlying mechanisms are unclear. In this study, we investigated the effect of a selective and potent thromboxane synthase inhibitor, DP-1904, on the release of eosinophil cationic protein (ECP) in platelet activating factor (PAF) and IgG-stimulated human blood eosinophils. PAF (1 μM) and IgG both released ECP which constituted about 25-30% of the total ECP content. The control protein, ovalbumin, did not release any ECP over the basal values. DP-1904 in two different concentrations, 10 μM and 100 μM, significantly attenuated the release of ECP in response to PAF or IgG. The mean percent inhibition by 10 μM DP-1904 was 49 ± 10 and 31 ± 2 against PAF and IgG-induced ECP release, respectively. However, at 100 μM DP-1904 the percent inhibition was 76 ± 14 and 67 ± 2, respectively. These data suggest that TXA2 is an important mediator in the regulation of eosinophil degranulation, and DP-1904 thus might prove beneficial in the treatment of bronchial asthma.
AB - Eosinophils have been recognized to be associated with various immune responses and disease processes including bronchial asthma. Eosinophils release a number of cytotoxic and neurotoxic mediators. However, the factors regulating such release and the underlying mechanisms are unclear. In this study, we investigated the effect of a selective and potent thromboxane synthase inhibitor, DP-1904, on the release of eosinophil cationic protein (ECP) in platelet activating factor (PAF) and IgG-stimulated human blood eosinophils. PAF (1 μM) and IgG both released ECP which constituted about 25-30% of the total ECP content. The control protein, ovalbumin, did not release any ECP over the basal values. DP-1904 in two different concentrations, 10 μM and 100 μM, significantly attenuated the release of ECP in response to PAF or IgG. The mean percent inhibition by 10 μM DP-1904 was 49 ± 10 and 31 ± 2 against PAF and IgG-induced ECP release, respectively. However, at 100 μM DP-1904 the percent inhibition was 76 ± 14 and 67 ± 2, respectively. These data suggest that TXA2 is an important mediator in the regulation of eosinophil degranulation, and DP-1904 thus might prove beneficial in the treatment of bronchial asthma.
UR - http://www.scopus.com/inward/record.url?scp=0031010685&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0031010685&partnerID=8YFLogxK
U2 - 10.1023/A:1027330506697
DO - 10.1023/A:1027330506697
M3 - Article
C2 - 9179617
AN - SCOPUS:0031010685
VL - 21
SP - 1
EP - 8
JO - Inflammation
JF - Inflammation
SN - 0360-3997
IS - 1
ER -